Search

Ion Beam Applications

Chiusa

10.54 -1.5

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

10.2

Massimo

10.8

Metriche Chiave

By Trading Economics

Entrata

-10M

Vendite

206M

P/E

Media del settore

41.111

63.778

Rendimento da dividendi

1.56

Margine di Profitto

-4.99

Dipendenti

1,943

EBITDA

-372K

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

1.56%

2.39%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

342M

Apertura precedente

12.04

Chiusura precedente

10.54

Ion Beam Applications Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 set 2024, 06:28 UTC

Acquisizioni, Fusioni, Takeovers

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Ion Beam Applications Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.